Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
|ClinicalTrials.gov Identifier: NCT00840463|
Recruitment Status : Terminated (Poor enrolment)
First Posted : February 10, 2009
Last Update Posted : June 12, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction||Drug: Ambrisentan Other: Placebo||Phase 4|
Hypothesis: patients with pulmonary hypertension secondary to diastolic congestive heart failure (CHF) treated with ambrisentan for 16 weeks will have improved hemodynamics, increased exercise capacity and improved functional class with an acceptable safety profile, compared with placebo treated patients.
Objectives: to evaluate the safety and efficacy of ambrisentan treatment in patients with pulmonary hypertension due to diastolic CHF. Efficacy will be assessed by improvement in hemodynamics (PVR(Pulmonary Vascular Resistance): primary efficacy endpoint), six minute walk distance (6MWD), World Health Organization (WHO) functional class and quality of life after 16 weeks of treatment with ambrisentan. Safety of ambrisentan will be compared to placebo.
Concomitant Medication: Treatment with standard medications for CHF including diuretics and optimal blood pressure control with antihypertensive medications will be allowed throughout the study period. Diuretics adjustment will also be allowed and encouraged based on the planned diuretic management protocol. Approved medications for CHF in general are allowed as well, though it should be noted that there are no medications shown to have benefit in diastolic CHF. Patients may not be on an endothelin antagonist or sildenafil.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction|
|Study Start Date :||January 2009|
|Primary Completion Date :||September 2013|
|Study Completion Date :||January 2014|
|Active Comparator: 1||
Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
Other Name: Letairis
|Placebo Comparator: 2||
Other Name: The placebo will look identical to the Ambrisentan tablets
- The primary outcome will be a safety evaluation. The primary efficacy outcome will be Pulmonary Vascular Resistance. [ Time Frame: Four months ]
- The secondary endpoints will be 6 MWD, WHO functional class, and SF-36 quality of life assessment. [ Time Frame: Four months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00840463
|United States, Texas|
|UT Southwestern Medical Center|
|Dallas, Texas, United States, 75390-8550|
|Principal Investigator:||Kelly M Chin, MD||UT Southwestern Medical Center|
|Principal Investigator:||Fernando Torres, MD||UT Southwestern Medical Center|